{"id":"W2912107322","doi":"10.1016/j.jtho.2019.02.001","title":"Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Daiichi Sankyo Company; Astellas Pharma Canada; Meso Scale Diagnostics; AbbVie; Takeda Pharmaceuticals North America; EMD Serono; Novartis; Bayer; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer","keywords":"Osimertinib; Medicine; Durvalumab; T790M; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer; Gefitinib; Erlotinib; Nivolumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00194629,0.00068538,0.001901483,0.0003015251,0.0003624924,0.001061204,0.0008016904,0.001250517,0.008237033],"category_scores_gemma":[0.002021106,0.0003118062,0.002020325,0.0003923729,0.0003845215,0.0007004891,0.0003427874,0.00255848,0.0007914406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001396527,"about_ca_system_score_gemma":0.001390496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001441098,"about_ca_topic_score_gemma":0.007276191,"domain_scores_codex":[0.9993351,0.0002808947,0.00007347428,0.0001106159,0.0001099728,0.00008995082],"domain_scores_gemma":[0.9986941,0.000350151,0.0003647977,0.00008225795,0.000109206,0.0003995671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7650735,0.007442881,0.003137698,0.00274731,0.003821943,0.0001757397,0.0001601447,0.001164293,0.01044983,0.0004035993,0.01528522,0.1901378],"study_design_scores_gemma":[0.5874313,0.3467053,0.02747465,0.0005550411,0.005391163,0.0003910097,0.0000708099,0.002208251,0.003324353,0.0004406688,0.02591426,0.00009305708],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9384685,0.03669982,0.0009808391,0.00373863,0.001800727,0.003729066,0.004280703,0.0001832745,0.01011832],"genre_scores_gemma":[0.9604059,0.01670139,0.002154847,0.003591411,0.001680287,0.002817943,0.004039726,0.00003931406,0.008569163],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008237033,"threshold_uncertainty_score":0.02755564,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02743526154477344,"score_gpt":0.4405778436775608,"score_spread":0.4131425821327874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}